MedTrace Logo

Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

NCT00683410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3366

Last updated 2010-11-16

Study results available
· View outcomes & findings →

Summary

To collect post-marketing information on the safety of Prevenar in Filipino patients

Conditions

  • Vaccines, Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683410 on ClinicalTrials.gov